Today, nearly everyone in America has become just as silly. People are “exactly like the pigeons,” says Peter Balsam, a ...

The reason why this nascent startup had VCs lining up is the founders.They are so famed in the AI world, everyone tried to hire them.

Women gather at a neighborhood square in Lilongwe, Malawi, on June 8 Women gather at a neighborhood square in Lilongwe, Malawi, on June 8Zafer Goder—Anadolu/Getty Images In Malawi, one in three women ...

The percentage of teachers who are using artificial intelligence-driven tools in their classrooms nearly doubled between 2023 and 2025, according to data from the EdWeek Research Center. In 2023, a ...

Still, being ghosted—when the other person disappears without explanation—can be shocking, hurtful and confusing to those being left on read. According to a new psychological analysis, the impulse to ...

Dr. Grant, a contributing Opinion writer, is an organizational psychologist at the Wharton School of the University of Pennsylvania. In ancient Greek mythology, a man who falls in love with his own ...

Imre Szenttornyay, CEO of Cielo IT LLC, empowers business owners to scale their operations profitably with AI-powered SmartSigns technology. When you manage a network of retail or franchise locations, ...

This transcript was prepared by a transcription service. This version may not be in its final form and may be updated. Belle Lin: Welcome to Tech News Briefing. It's Tuesday, December 23rd. I'm Belle ...

When I last covered the self-styled TechBio company Recursion Pharmaceuticals, Inc. (RXRX) in early October, I was attempting to find reasons why the company's share price was on the rise, up from ~$4 ...

Recursion Pharmaceuticals Inc (NASDAQ: RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight from Neutral and lifted its price target to $11 from $10. What Happened: ...

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

The clinical-stage biotech might have a successful drug on its hands, if a relatively early-stage clinical trial is any indication. Its REC-4881 did very well in the testing. Before market open, ...